HOME >> BIOLOGY >> NEWS
Anthrax inhibitors identified by Burnham team

June 20, 2005 (La Jolla, CA). A collaborative team of scientists led by The Burnham Institute's Maurizio Pellecchia, Ph.D., has identified inhibitors of the anthrax toxin, termed lethal factor ("LF") that could be developed into an emergency treatment for exposure to inhalation anthrax. These findings will be published by the Proceedings of the National Academy of Sciences by Early Edition at the journal's website the week of June 20th.

Bacillus anthracis ("anthrax") is a proven agent of biological terrorism. Pulmonary anthrax, in which spores of the anthrax bacteria are inhaled, is typically fatal unless diagnosis is made at an early stage of infection, when antibiotics such as Ciprofloxacin can provide a complete cure. At late stages in the disease, antibiotics can kill the anthrax bacteria, but do not affect LF secreted by the bacteria, which is sufficiently concentrated in the bloodstream. LF enters cells and inactivates a human protein called "mitogen-activated protein kinase", or "MAPKK", disrupting the normal signaling pathways of the cell and inducing cell-death.

Using a fragment-based approach based on assays conducted with highly sensitive nuclear magnetic resonance ("NMR") techniques developed in Dr. Pellecchia's laboratory, the scientists were able to identify a scaffold that served as a template for designing a preferred structure for small-molecule inhibitors of LF. Lead compounds were synthesized and validated as highly potent and selective against LF in vitro. In in vitro assays, the compounds did not affect prototype human metalloproteinase enzymes that are structurally similar to LF. This is very important as selectivity is a fundamental prerequisite for a drug to be safe for use in humans.

Three lead compounds where tested in mice infected with anthrax spores, in combination with the antibiotic Ciprofloxacin. The survival rate for mice treated with each of the compounds tested in the combination therapy was two-fo
'"/>

Contact: Nancy Beddingfield
nbeddingfield@burnham.org
858-646-3146
Burnham Institute
20-Jun-2005


Page: 1 2

Related biology news :

1. Anthrax bacteriums deadly secrets probed
2. Anthrax paralyzes immune cells with lethal toxin, UF research shows
3. Anthrax inhibitor counteracts toxin, may lead to new therapeutics
4. Anthrax spores may survive water treatment
5. Anthrax stops body from fighting back, study shows
6. Anthrax test, developed by army and CDC, receives FDA approval
7. COX-2 inhibitors delay pancreatic cancer precursors in mice
8. Green tea and COX-2 inhibitors combine to slow growth of prostate cancer
9. Forsyth scientists find linkages between serotonin reuptake inhibitors and bone mass
10. Aromatase inhibitors: A treatment of choice for advanced breast cancer patients
11. Sweet water taste paradoxically predicts sweet taste inhibitors

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:8/26/2020)... ... August 25, 2020 , ... Mitotech ... partnership with Essex Bio-Technology, a bio-pharmaceutical company specializing in Ophthalmology and Dermatology, ... of SkQ1 ophthalmic solution in patients with moderate to severe Dry Eye ...
(Date:8/23/2020)... WOODLANDS, Texas (PRWEB) , ... August 21, 2020 ... ... from Rigaku Corporation has been published and is now available on ... single crystal X-ray diffraction—serves the X-ray analysis community, presenting current news and crystallographic ...
(Date:8/21/2020)... ... 2020 , ... The 19th Annual Bio-IT World Conference ... informatics and IT leaders goes VIRTUAL and announces its updated event features and ... takes the leadership role of keeping our life science community connected by bringing ...
Breaking Biology News(10 mins):
(Date:8/3/2020)... ... August 03, 2020 , ... Introducing Ardent Animal Health – MediVet Biologics rebrands ... , Known as MediVet Biologics since its formation in 2016, the company is ... Animal Health will build on its base of innovative therapies for osteoarthritis and cancer. ...
(Date:7/31/2020)... N.J (PRWEB) , ... July 29, 2020 , ... ... company, and Catalent, the leading global provider of advanced delivery technologies, development, and ... today announced that they have entered into a strategic partnership whereby Catalent will ...
(Date:7/18/2020)... , ... July 16, 2020 , ... After research model ... completion of a great surgery is only the beginning of a successful study, while ... community. , Join Brad Gien, Global Head of Surgery from Envigo in ...
(Date:7/10/2020)... ... July 09, 2020 , ... ... of Technology (MIT) has expanded the company’s exclusive license to include clinical ... the point-of-care diagnostic market, focusing initially on the SARS-CoV-2 biosensor. CANARY’s™ ...
Breaking Biology Technology:
Cached News: